Limited sequence polymorphisms of four transmission-blocking vaccine candidate antigens in Plasmodium vivax Korean isolates by Jung-Mi Kang et al.
Kang et al. Malaria Journal 2013, 12:144
http://www.malariajournal.com/content/12/1/144RESEARCH Open AccessLimited sequence polymorphisms of four
transmission-blocking vaccine candidate antigens
in Plasmodium vivax Korean isolates
Jung-Mi Kang1†, Hye-Lim Ju1†, Sung-Ung Moon2, Pyo-Yun Cho3, Young-Yil Bahk4, Woon-Mok Sohn1,
Yun-Kyu Park3, Seok Ho Cha3, Tong-Soo Kim3* and Byoung-Kuk Na1*Abstract
Background: Transmission-blocking vaccines (TBVs), which target the sexual stages of malaria parasites to interfere
with and/or inhibit the parasite’s development within mosquitoes, have been regarded as promising targets for
disrupting the malaria transmission cycle. In this study, genetic diversity of four TBV candidate antigens, Pvs25,
Pvs28, Pvs48/45, and PvWARP, among Plasmodium vivax Korean isolates was analysed.
Methods: A total of 86 P. vivax-infected blood samples collected from patients in Korea were used for analyses.
Each of the full-length genes encoding four TBV candidate antigens, Pvs25, Pvs28, Pvs48/45, and PvWARP, were
amplified by PCR, cloned into T&A vector, and then sequenced. Polymorphic characteristics of the genes were
analysed using the DNASTAR, MEGA4, and DnaSP programs.
Results: Polymorphism analyses of the 86 Korean P. vivax isolates revealed two distinct haplotypes in Pvs25 and
Pvs48/45, and three different haplotypes in PvWARP. In contrast, Pvs28 showed only a single haplotype. Most of the
nucleotide substitutions and amino acid changes identified in all four TBV candidate antigens were commonly
found in P. vivax isolates from other geographic areas. The overall nucleotide diversities of the TBV candidates were
much lower than those of blood stage antigens.
Conclusions: Limited sequence polymorphisms of TBV candidate antigens were identified in the Korean P. vivax
population. These results provide baseline information for developing an effective TBV based on these antigens,
and offer great promise for applications of a TBV against P. vivax infection in regions where the parasite is most
prevalent.
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Malaria is one of the most important infectious diseases
and remains a significant global public health problem
[1]. Although extensive studies have aimed to inform the
development of an effective malaria vaccine, no licensed
vaccine against malaria has yet emerged. A number of po-
tential malaria vaccine candidates are under various stages
of clinical development [2], but their antigenic diversity* Correspondence: tongsookim@inha.ac.kr; bkna@gnu.ac.kr
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reproduction in any medium, provided the oramong clinical isolates is one of the major obstacles in the
design of an effective malaria vaccine. Therefore, under-
standing the epidemiology of the parasite and the genetic
polymorphisms of vaccine candidate antigens in world-
wide clinical isolates is critically important for the success-
ful development of a malaria vaccine.
Transmission-blocking vaccines (TBVs), which target
the sexual stages of malaria parasites to interfere with
and/or block the parasite’s development within mosqui-
toes, have been regarded as important targets for dis-
rupting the malaria transmission cycle [3-5]. In particular,
TBVs have been considered as a promising strategy for
controlling Plasmodium vivax, since this parasite has a
unique biological characteristic in which it undergoes earlyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Oligonucleotide primers used in this study
Primer name Sequences
Pvs25 Pvs25 F 5′-ACCATCCGAGCGGAAAGGAAC-3′
Pvs25 R 5′-GTCGGTAAGTTCAGTAAAGAA-3′
Pvs28 Pvs28 F 5′-CGATTCCCCCTCCCCACTTTT-3′
Pvs28 R 5′-GTGTATGTTTGTGTGTGTGTG-3′
Pvs48/45 Pvs48/45 F 5′-ATGTTGAAGCGCCAGCTCGCCAACC-3′
Pvs48/45 R 5′-TCAGAAGTACAACAGGAGGAGCACAAT-3′
PvWARP PvWARP F 5′-ATGAAAGGCGCACACGCCGTGTCC-3′
PvWARP R 5′-TCAGTCCGTAGAGTCGCTGTCCCC-3′
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symptoms, which enables parasite transmission prior to
treatment. To date, several sexual stage antigens with po-
tent transmission blocking activities have been identified
and characterized. These include the pre-fertilization anti-
gen, Pvs48/45, and the post-fertilization antigens, Pvs25
and Pvs28. Pvs25 and Pvs28, the most extensively studied
TBV candidate antigens of P. vivax, are specifically ex-
pressed on the surfaces of the zygotes and ookinetes of the
malaria parasite [6], and play an essential role in both
the survival of ookinetes in the mosquito midgut and in
the subsequent penetration of the midgut epithelium and
transformation into oocysts [7]. These proteins have been
shown to exhibit strong immunogenicities and potent
transmission blocking activities [8-13], thus supporting
their potential for TBVs. More recently, several other
P. vivax proteins have been identified and partially char-
acterized as potential antigens for a mosquito-stage TBV,
including Pvs230 [14,15], chitinase (PvCHT1) [16,17], the
circumsporozoite thrombospondin-related anonymous
protein-related protein (PvCTRP) [18], and the von
Willebrand factor A domain-related protein (PvWARP)
[19,20]. However, genetic polymorphism in these vaccine
candidate antigens can hamper the efficacy of a vaccine.
Therefore, identifying genetic variations in sexual stage
antigen genes among the P. vivax population is an im-
portant task for designing effective anti-malarial control
measures.
In this study, genetic variations of four TBV candi-
date antigens, Pvs25, Pvs28, Pvs48/45, and PvWARP,
in P. vivax Korean isolates were analysed. These TBV
candidate antigens showed highly limited sequence poly-
morphisms and lower nucleotide diversities compared to
those observed in blood stage antigens. These results col-
lectively support the potential of the antigens as promising
targets for P. vivax TBV vaccine development.
Methods
Blood samples
A total of 86 blood samples, which were collected from
Korean patients infected with P. vivax in Korea between
1999 and 2010, were used in this study [21]. Plasmo-
dium vivax infection was confirmed by microscopic
examination of thin blood smears and polymerase chain
reaction (PCR) [22]. All patients had a typical febrile ill-
ness and had not been abroad, especially where malaria
is endemic, for at least two years when their blood sam-
ples were collected. Approximately 5 ml of blood was
collected from each individual, which was separated into
packed cells and plasma and stored at −80°C until use.
Blood collections were conducted after obtaining in-
formed consent from the patients and by adhering to the
institutional ethical guidelines reviewed and approved by
either the Ethics Committee of Gachon University ofMedicine and Science or the Inha University School of
Medicine.Genomic DNA extraction and amplification of TBV
candidate antigens
Genomic DNA was extracted from 200 μl of each blood
sample using a QIAamp Blood Kit (Qiagen, Valencia,
CA, USA). Amplification of TBV candidate antigens was
performed with PCR by using specific primers for each
antigen (Table 1). These primers were designed to amp-
lify full-length gene of each antigen. The amplification
reactions for Pvs25, Pvs28, and PvWARP were per-
formed using the following thermal cycling conditions:
94°C for 5 min, 30 cycles at 94°C for 1 min, 52°C for 1 min,
and 72°C for 1 min, followed by a final extension at 72°C
for 10 min. Amplification of Pvs48/45 was conducted with
the following thermal cycling conditions: 94°C for 5 min,
30 cycles at 94°C for 1 min, 55°C for 1 min, and 72°C for
1.5 min, followed by a final extension at 72°C for 10 min.
In order to reduce the likelihood of possible nucleotide
misincorporations, Ex Taq DNA polymerase (Takara,
Otsu, Japan) with a proof-reading function was used in all
the PCR reactions. The PCR product was analysed on a
1.2% agarose gel, purified from the gel, and then ligated
into the T&A cloning vector (Real Biotech Corporation,
Banqiao City, Taiwan). Each ligation mixture was
transformed into Escherichia coli DH5α competent cells,
and positive clones with the appropriate insert were se-
lected by colony PCR. The nucleotide sequences of the
cloned inserts were analysed by automatic DNA sequen-
cing. In order to verify the sequences, at least three clones
from each isolate were sequenced in both directions. Some
isolates underwent two or three-fold sequence coverage to
confirm the presence of rare polymorphisms. The nucleo-
tide sequences reported in this study have been deposited
in the GenBank database under the accession numbers
JX667760–JX667767 (Pvs25, JX667760–JX667761; Pvs28,
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Figure 1 Polymorphism analysis of Pvs25 in Plasmodium vivax
Korean isolates. (A) Distribution of the most commonly identified
amino acid variants in Pvs25 among global isolates of Plasmodium
vivax. Dot represent identical amino acid residue compared to Sal I.
1[This study], 2[37], 3[32], 4[35], 5[33], 6[ABG29073], 7[36], 8[31], 9[9], 10[32],
11[ABG29072], 12[31], 13[34], 14[32], 15[32], 16[32], 17[32], 18Signal peptide
region. (B) Annual distribution of Pvs25 haplotypes during the study
period, 1999–2010. The 86 Pvs25 sequences from Korean isolates were
analysed as per the year of collection.
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Nucleotide and deduced amino acid sequences of each
gene were analysed using EditSeq and SeqMan in the
DNASTAR package version 4.0 (DNASTAR, Madison,
WI, USA). DNA sequence polymorphism analyses were
performed on all 86 sequences of each TBV antigen. The
number of segregating sites (S), haplotype diversity (Hd),
nucleotide diversity (π), and the average number of pair-
wise nucleotide differences within the population (K) were
calculated using the DnaSP ver. 5.10.00 package [23]. The
numbers of synonymous (dS) and non-synonymous (dN)
substitutions were estimated and compared by the Z-test
(P < 0.05) in the program MEGA4 [24], using the Nei and
Gojobori’s method [25] with the Jukes and Cantor correc-
tion. The standard error was determined by 1,000 boot-
strap replications.
Results and discussion
Plasmodium vivax re-emerged in South Korea in 1993
and remains a significant public health problem in the
country. The outbreak has continued with fluctuating
numbers of annual indigenous cases since the re-
emergence, with total accumulated cases of up to 32,000,
although the number of annual cases is currently decreas-
ing [26]. Several recent studies have strongly suggested
that the genetic diversity of P. vivax Korean isolates has
rapidly disseminated in recent years [21,27-29], and that
local transmission of the parasite is possibly established in
South Korea. Therefore, understanding the nature of gen-
etic polymorphism of P. vivax circulating in South Korea
will be helpful for understanding the nationwide parasite
heterogeneity and for the implementation of malaria con-
trol programes in the country, as well as for the develop-
ment of an effective vaccine. In this study, the genetic
diversity of four TBV candidate antigens, Pvs25, Pvs28,
Pvs48/45, and PvWARP, were analysed.
The gene encoding Pvs25 was successfully amplified
from the 86 P. vivax Korean isolates. Compared to the
Sal I sequence, the 86 Pvs25 sequences showed polymor-
phisms at three nucleotide sites (G289C, T389C, and
T639A), of which two nucleotide substitutions resulted in
amino acid changes (E97Q and I130T). One nucleotide
substitution (T639A) resulted in a synonymous amino
acid substitution and this nucleotide substitution was con-
served in all 86 sequences. Pvs25 consists of three parts,
which are characterized by an N-terminal signal peptide
sequence followed by four epidermal growth factor (EGF)-
like domains and a glycosylphosphatidylinositol (GPI) an-
chor [6]. The amino acid substitution E97Q was located in
the second EGF-like domain (EGF-2), while the I130T
substitution was found in the third EGF-like domain
(EGF-3) (Figure 1A). These amino acid changes classified
the Korean isolates into two different haplotypes; haplo-
types A and B. The E97Q substitution was found in onlyhaplotype A, while the I130T substitution was conserved
in both haplotypes. Compared to previously reported
Pvs25 sequences from worldwide P. vivax isolates, the
amino acid substitutions found in the Korean isolates were
commonly identified in isolates from other Asian coun-
tries and no novel amino acid changes were identified.
Haplotype B was more prevalent (69.8%) than haplotype
A (30.2%) and no difference was found in the annual preva-
lence of these haplotypes (Figure 1B).
In comparison with the Sal I sequence, the 86 Pvs28 se-
quences showed nucleotide polymorphisms at three posi-
tions, A154C, T346C, and C419G, which were evenly
distributed in all 86 sequences, resulting in only one hap-
lotype (haplotype 1). Two nucleotide substitutions (A154C
and C419G) resulted in non-synonymous amino acid sub-
stitutions (M52L and T140S), and the other (T346C) re-
vealed a synonymous amino acid substitution (Table 2).
Table 2 Amino acid variations identified in Pvs28 of Plasmodium vivax Korean isolates
Isolates Signal9 EGF-1 EGF-2 EGF-3 EGF-4 THR11
5 52 53 65 98 105 106 110 116 140 159 Repeat10 224
Sal I H M A T L E V Y L T K 6 I
South Korea1 • L • • • • • • • S • 7 •
South Korea2 • L • • • • • • • S • 6 •
China3 • M/L • • L/I E/K • • L/V T/S • 5−6 I/M
Iran4 • L • T/K • • • • • S • 4−6 •
Bangladesh5 • M/L • T/K L/I • V/E N L/V T/S K/R 5−7 I/M
India6 H/Y/T M/L A/V T/K L/I E/K • • L/V T/S • 3−6 I/M
Thailand7 • M/L A/V T/K L/I E/K V/E N L/V T/S • 5−7 •
Mexico8 • L • • • • • • • S • 5−6 •
1[This study], 2[37], 3[35], 4[33], 5[31], 6[36], 7[9], 8[34], 9Signal peptide region, 10the copy number of the GSGGE/D tandem repeats; 11the C terminal hydrophobic




























































Figure 2 Polymorphism analysis of Pvs48/45 in Plasmodium
vivax Korean isolates. (A) Comparison of amino acid variants
between three haplotypes of Pvs48 Korean Plasmodium vivax and
Sal I. Dot represent identical amino acid residue compared to Sal I.
(B) Annual distribution of Pvs48/45 haplotypes during the study
period, 1999–2010. The 86 Pvs48/45 sequences from Korean isolates
were analysed by year of collection.
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http://www.malariajournal.com/content/12/1/144Pvs28 has a conserved structure, which consists of an
N-terminal signal peptide sequence, four EGF domains,
tandem repeat sequences (Gly-Ser-Gly-Gly-Gln/Asn;
GSGGE/D), and a GPI anchor [6]. Amino acid substitu-
tions M52L and T140S were identified in the EGF-1 do-
main and the EGF-3 domain, respectively. The two amino
acid changes found in the 86 Pvs28 sequences were com-
monly identified in sequences from isolates from different
countries. All of the 86 Pvs28 sequences contained seven
copies of the GSGGE/D tandem repeat at the end of the
EGF-4 domain.
Pvs25 and Pvs28 are the most advanced TBV candidates
[10,11,30], which show limited polymorphisms among
worldwide P. vivax isolates and the polymorphisms
present in clinical isolates do not appear to hamper the ef-
ficacy of the candidate antigens as TBVs [8-13]. The amino
acid changes found in Pvs25 and Pvs28 among the Korean
isolates were not novel, but are commonly identified in
previously studied worldwide P. vivax isolates [9,31-36].
Interestingly, the overall genetic polymorphisms of the 86
Pvs25 and Pvs28 sequences were more limited than those
previously analysed in Korean isolates [37]. With respect
to Pvs25, the main amino acid substitutions, E97Q and
I130T, were commonly identified in the samples analysed
in this study and in the previous report. However, several
minor amino acid substitutions that were found in very
low frequencies in a small number of isolates in the previ-
ous study [37] were not identified in this study. With re-
spect to Pvs28, the minor amino acid changes in the
tandem repeat region of the EGF-4 domain observed in
the previous study [37] were not found in the 86 se-
quences analysed in the current study. These results col-
lectively suggest that genetic polymorphism of the Pvs25
and Pvs28 genes in Korean P. vivax isolates is more lim-
ited than previously presumed.
Pvs48/45 is a homologous protein with Pfs48/45, which
is expressed on gametocytes and gametes of Plasmodium
falciparum and appears to be involved in the fertilizationprocess and zygote formation [38]. Because antibodies
against Pfs48/45 inhibit infection and development of
P. falciparum in mosquitoes at an early stage, presum-
ably by inhibiting parasite fertilization, it is thus regarded
as a TBV candidate antigen [39]. Pvs48/45 is still awaiting
pre-clinical study, but its potential as a target of TBV has
been addressed previously [40]. A total of 86 Pvs48/45 se-
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Figure 3 Polymorphism analysis of PvWARP in Plasmodium
vivax Korean isolates. (A) Comparison of amino acid variants
between two haplotypes of PvWARP Korean Plasmodium vivax and
Iranian isolates [44]. Dot represent identical amino acid residue
compared to Sal I. (B) Annual distribution of PvWARP haplotypes
during the study period, 1999–2010. The 86 PvWARP sequences
from Korean isolates were analysed by year of collection.
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http://www.malariajournal.com/content/12/1/144Korean isolates. Compare to the Sal I sequence, the 86
Pvs48/45 sequences showed nucleotide polymorphism at
seven sites (G103A, C631A, C750A, G1003T, G1126A,
T1139C, and A1235G), which resulted in dimorphic poly-
morphisms at seven amino acid positions (E35K, H211N,
K250N, D335Y, A376T, I380T, and K418R). No synonym-
ous nucleotide polymorphism was identified in the se-
quences. Based on these amino acid substitutions, Pvs48/
45 of the Korean isolates were classified into three differ-
ent haplotypes; haplotypes A, B, and C (Figure 2A). The















Pvs25 86 1 0 1 1
Pvs28 86 0 0 0 0
Pvs48/45 86 2 0 2 2
PvWARP 86 1 0 1 1
K, average number of pair-wise nucleotide differences; H, number of haplotypes; Hd
dN, number of nonsynonymous substitutions; dS, number of synonymous substitutA376T, and K418R, were conserved in all 86 Pvs48/45
sequences. The E35K substitution was found in haplo-
types B and C, while the I380T amino acid change was
found in only haplotype C. The frequency and annual
distribution of the Pvs48/45 haplotypes revealed that hap-
lotype A (37.2%) and haplotype B (48.8%) were prevalent
and their frequencies did not vary significantly across
years (Figure 2B).
WARP is a highly conserved, soluble protein that is
expressed in the late ookinetes and early oocysts of mal-
aria parasites [19,41]. The protein mediates ookinete at-
tachment to the mosquito midgut, differentiation of
ookinetes to oocysts, and interactions with the mosquito
basal lamina. Passive immunization of an anti-WARP
antibody significantly reduced Plasmodium development,
which suggested its potential as a TBV candidate antigen
[42,43]. Plasmodium falciparum WARP (PfWARP) is
known to show limited polymorphism in clinical isolates
[43]. PvWARP also showed high sequence conservation
among clinical P. vivax isolates from Iran [44]. Sequence
analysis of the 86 PvWARP sequences revealed a total of
four nucleotide substitutions (A247G, A531T, C533T, and
C744A) compared to the Sal I sequence. These nucleotide
substitutions resulted in non-synonymous amino acid
changes (T83A, R177S, P178L, and D248E) (Figure 3A).
Two of the amino acid substitutions (T83A and R177S)
were previously reported from P. vivax isolates collected
in Iran [44], but the other changes (P178L and D248E)
have not been reported previously. A sequence analysis
of the deduced amino acid sequences classified the 86
PvWARP into two different haplotypes (haplotypes 1
and 2), in which the P178L amino acid substitution was
identified only in haplotype 2, while the other three amino
acid changes were conserved in both the haplotypes.
Haplotype 2 was predominant (95.3%) in all tested years
and only four isolates of haplotype 1 were found in 2000,
2003, 2005, and 2009 (Figure 3B).
One of the major obstacles in the development of an
effective malaria vaccine is the genetic polymorphism of
genes encoding potential vaccine candidate antigens inof neutrality at TBV candidate antigens among Korean
l no. of
ations
K H Hd ± SD π ± SD dN dS
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, haplotype diversity; π, observed average pair-wise nucleotide diversity;
ions.
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that TBV candidates have limited polymorphism com-
pared to blood stage vaccine candidate antigens
[14,33,34,45]. Since blood stage antigens are targets of
host antibody responses, it is thereby likely that they
would evolve high genetic diversity to increase the para-
site’s immune evasion. Analysis of nucleotide diversity
and genetic differentiation of four TBV candidate anti-
gens of the 86 Korean isolates also revealed that limited
genetic diversity was identified in Korean P. vivax iso-
lates. The average number of pair-wise nucleotide differ-
ences (K) for Pvs25, Pvs28, Pvs48/45, and PvWARP was
0.427, 0.000, 0.716, and 0.090, respectively (Table 3). The
overall haplotype diversity (Hd) was 0.427 ± 0.040, 0.000,
0.611 ± 0.026, and 0.090 ± 0.041 for Pvs25, Pvs28, Pvs48/
45, and PvWARP, respectively (Table 3). As expected,
the overall nucleotide diversities of the four TBV candi-
dates, Pvs25 (π = 0.00065), Pvs28 (π = 0.00000), Pvs48/45
(π = 0.00053), and PvWARP (π = 0.00010), were much
lower than those of blood stage proteins such as the
C-terminal 42 kDa region of the merozoite surface
protein-1 (PvMSP-142; π = 0.01586) [21] and the Duffy
binding protein (PvDBP; π = 0.00299) [46], which were de-
termined from the same P. vivax isolates used in this
study. Previous studies have suggested that the antigenic
variation of Pvs25 is more limited than that of Pvs28
[6,35]; however, in the Korean isolates, the nucleotide di-
versity of Pvs28 was lower than that of Pvs25, as only a
single haplotype of Pvs28 was identified. Polymorphism
analyses of several blood stage antigens, including MSP-1,
MSP-3α, and DBP, have strongly suggest that the genetic
diversity of Korean P. vivax population has rapidly dissem-
inated in recent years [21,27-29]. However, in the present
study, there was no evidence of genetic discrimination in
any of the TBV candidates during the tested years, since
no significant correlations were identified between the
haplotypes and their annual distributions. Balancing selec-
tion has been inferred to maintain high levels of poly-
morphism in PvMSP-142 [21] and PvDBP [46] in P. vivax
Korean isolates. The dN was slightly greater than the dS
in Pvs25, Pvs48/45, and PvWARP, suggesting the possible
action of positive natural selection, but the differences
were not significant.
Conclusions
The results of the present study are in agreement with
previous observations that TBV candidate antigens of
P. vivax show highly limited sequence polymorphisms.
No evidence for annual genetic variation of these antigens
was also identified in Korean isolates. The limited genetic
diversity of sexual stage antigens is most likely attributed
to the expression of these proteins across mosquito stages,
which might avoid immune pressure in the humans. The
limited polymorphism observed in these TBV candidateantigens among P. vivax Korean isolates can provide use-
ful baseline information for developing an effective TBV
based on these antigens, for predicting the performance of
the TBV, and to help identify polypeptide regions suitable
for designing vaccines.
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